In line with Lipidor's strategy, the company continuously reviews and works to further strengthen and expand patent protection for its AKVANO®-technology. The new patent application is based on the development work carried out over the past year, which led to an updated formulation of the company's most important drug candidate for the treatment of psoriasis, AKP02G2. The new patent application (a so-called priority application) was filed with the European Patent Office (EPO) on October 27, 2023, and also covers the use of the formulation technology in other treatment areas.

“In AKP02G2, the interaction of the formulation with the different layers of the skin has been optimized, which we expect will lead to an improvement in the deposition and efficacy of the active substances,” said Jan Holmbäck, CSO at Lipidor.

With the new patent application, AKP02G2 and a number of other applications of the technology (subject to approval by the patent authorities) will be patent protected until 2044.

“We already have solid patent protection, but of course we are very positive about the opportunities that are opened up through potentially strengthening and extending protection for our technology,” says Ola Holmlund, CEO of Lipidor. “The patent application protects the development investments that have been made and if the application is approved, it is very likely to generate commercial value.”

Publication
The information was provided for publication by Lipidor’s CEO on 27 October 2023 at 9.45 am (CEST).